Kornimate/medical-research-clean huggingface dataset:
study of the integration success of an implant system with a novel abutment attachment design in immediate loading cases

Conditions: Partial Edentulism; Tooth Disease

Summary: integration success rates measured by lack of implant mobility and crestal bone regression measurement will be higher for the experimental implant design than for the control implants.

in this study patients are randomized to receive either the experimental implant system or the control nanotite certain tapered (standard abutment connection) and assessed for integration success measured by cumulative success rate in cases that are loaded immediately

Eligibility criteria:
inclusion criteria: * patients of either sex and older than 18 years of age * patients needing at least one dental implant to treat partial edentulism * patients physically able to tolerate surgical and restorative dental procedures * patients agreeing to all protocol visits exclusion criteria: * patients with infection or severe inflammation at the intended treatment sites * patients smoking greater than 10 cigarettes per day * patients with uncontrolled diabetes mellitus * patients with uncontrolled metabolic diseases * patients who received radiation treatment to the head in the past 12 months * patients needing bone grafting at the intended treatment sites * patients known to be pregnant at screening visit * patients with para-functional habits like bruxing and clenching

Keywords: clinical study edentulism dental implants nanotite certain tapered implant randomized crestal bone level immediate loading
behavioral parenting skills as a novel target for improving pediatric medication adherence: study 3

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Summary: the current study will assess the acceptability and feasibility of the caremeds intervention with a larger sample (n = 100) across multiple sites in buffalo, ny, and atlanta, ga.

this is a pilot randomized controlled trial of the caremeds program to assess feasibility and obtain preliminary efficacy data among families of young children (ages 3-9) with all. the objective of this aim is to implement our study procedures and study conditions (caremeds vs. usual care control). we hypothesize that pilot findings will support the feasibility of the intervention and suggest important improvements in our behavioral secondary outcomes (i.e., behavioral parenting skills, medication adherence

Eligibility criteria:
inclusion criteria: * parent of a child who is diagnosed and being treated for any type of acute lymphoblastic leukemia (all) at a study site. * parent has primary medication responsibility. * pediatric patient aged 3-9 years * child on therapy that includes home-based oral anti-cancer medication taken at home, such as 6-mp. * parent has verbal english or spanish fluency. * participant must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure exclusion criteria: * parent of a child who is not diagnosed nor being treated for any type of acute lymphoblastic leukemia (all) at a study site. * parent does not have primary medication responsibility. * pediatric patient aged 3-9 years * pediatric patient is not on therapy that includes oral anti-cancer medication (e.g., 6-mp). * parent does not have verbal english or spanish fluency. * parent is unwilling or unable to follow protocol requirements
culturally sensitive intervention to improve retention in hiv care for latino msm

Conditions: HIV

Summary: the goal of this proposal is to culturally adapt and tailor an existing, theory-based intervention, using state-of-the-art methods designed to maximize cultural sensitivity, feasibility and acceptability to hiv+ latino msm, and to test it in a small randomized controlled trial (n=60 intervention; n=60 control).

while early receipt of and adherence to antiretroviral therapy are critical for effective hiv treatment, engagement with and retention in hiv care are essential first steps. retention in hiv care is particularly important for traditionally disadvantaged groups, such as latino msms, who are over-represented in the hiv epidemic. hiv+ latino msm therefore urgently need interventions to improve their retention in hiv care, which may be affected by a number of culture-specific factors. the goal of this proposal is to culturally adapt and tailor an existing, theory-based intervention, using state-of-the-art methods designed to maximize cultural sensitivity, feasibility and acceptability to hiv+ latino msm, and to test it in a small randomized controlled trial (n=60 intervention; n=60 control). the study will be conducted among insufficiently retained hiv+ latino msm at altamed, the largest provider of hiv medical services for latinos in los angeles. the proposed intervention is designed to retain participants in hiv care by addressing barriers to and facilitators of hiv care salient to latinos, using group-based as well as one-on-one, peer-based learning approaches.

Eligibility criteria:
inclusion criteria include: 1) being hiv+; 2) \> 18 years old; 3) male; 4) fluent in spanish; 5) self-identify as having latino or hispanic ethnicity; 6) self-identify as gay or as ever having sex with men; 7) must have scheduled visit with altamed in the prior 12 months and have a) fewer than one visit in the prior four months or b) detectable viral load exclusion criteria include 1) not having a scheduled visit with altamed in the prior 12 months and having a) more than one visit in the prior four months or b) undetectable viral load; 2) being unable to give informed consent; 3) lack of spanish language skills
comparative effectiveness of the minimally invasive coronary artery bypass grafting

Conditions: Coronary Artery Disease; Myocardial Ischemia; Heart Diseases

Summary: the purpose of this study is to compare three different revascularization strategies in patients with multi-vessel coronary disease: mics cabg, opcabg and oncabg. the study hypothesis: mics cabg (minimally invasive cardiac surgery coronary artery bypass grafting) has advantages in comparison with conventional off-pump (opcabg) and on-pump coronary artery bypass grafting (oncabg) concerning major adverse cardiac and cerebral events (macce) and procedural success.

prospective, single-center, randomized trial, intended to compare three different revascularization strategies in patients with multi-vessel coronary artery disease: 1. mics cabg. minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy). (mics cabg group, n=50). 2. opcabg. off-pump coronary artery bypass grafting treatment (opcabg group, n=50). 3. oncabg. on-pump coronary artery bypass grafting treatment (oncabg group, n=50). the endpoints: the primary endpoints will be death, mi, stroke, or new myocardial ischemia and will be target vessel revascularization and non-target vessel revascularization at 30 days, 12 months and 3-year follow-up. the secondary endpoints: procedural success, procedural and post-procedural blood loss and number of transfusions, wound complications, recovery time, heart failure (new york heart association (nyha)), life quality assessed by one of the life quality questionnaires.

Eligibility criteria:
inclusion criteria: * multi-vessel coronary artery disease with ≥ 70% artery stenosis (according to qca) * ii-iv canadian cardiovascular society functional class of angina * patients at 1 month after acute myocardial infarction * ability to perform either of revascularization methods (mics cabg, opcabg, oncabg) * patients must have signed an informed consent exclusion criteria: * pregnancy. * acute coronary syndrome. * previous cabg. * severe comorbidity with high procedural risk for either of the studied strategies. * mental diseases which block the revascularization procedure. * severe peripheral artery disease. * other serious diseases limiting life expectancy (e.g. oncology) * inability for long-term follow-up. * participation in other clinical trials. * single vessel disease. * need for emergency revascularization (acute mi, acute coronary syndrome etc.)

Keywords: mics cabg opcabg oncabg cad
efficacy and safety of therapy with tri-luma® cream in sequence with glycolic acid peels for melasma

Conditions: Melasma

Summary: to determine the effectiveness and safety of sequential therapy with of tri-luma® cream and a series of glycolic acid peels in treatment of moderate to severe melasma.

to determine the efficacy and safety of sequential therapy with fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%, and a series of glycolic acid peels in the treatment of moderate to severe melasma.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with moderate to severe melasma exclusion criteria: * subjects under treatment for a dermatologic condition, which may interfere with the safe evaluation of the study combination (e.g. eczema, psoriasis, severe sun-damage, dermatitis) * subjects with a diagnosis of skin cancer (bce, scc, melanoma) in the areas to be treated
computerized adaptative testing of self-perceived quality of care in psychiatry

Conditions: Mental Disorders

Summary: objectives 1. to develop and validate a computerized adaptative testing (cat) of self-perceived quality of care in psychiatry. 2. to analyze the implementation of this new measure in clinical practice : qualitative analysis of the relationship patient/professional.

prospective and multicentric study 1. development and validation of the cat. 4 steps : * elaboration of a pool of items, based on literature review and interview with patients. * selection of the most relevant items based on a qualitative approach using cognitive interview with patients. * calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning. * metrological validation of the cat. 2. analysis of the implementation of the cat in clinical practice using interview with professionals and patients.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia, bipolar disorder or depression according dsm v * criteria * age over 18 years * informed consent to participate * french as the native language exclusion criteria: * diagnosis other than schizophrenia, bipolar disorder or depression according dsm v criteria * decompensated organic disease, and mental retardation
value of copeptin assay in children with febrile seizures at sohag university hospital

Conditions: Febrile Seizure

Summary: febrile seizures are one of the most common clinical diseases in pediatric neurology. it occurs between 6 months and 6 years of age and occurs in \~2-5% of children. according to the age, frequency, duration, and type of seizures fs is divided into simple febrile seizures and complex febrile seizures differentiation between febrile seizures and non-ictal events associated with fever such as shivering or dizziness is challenging. therefore, precise diagnosis of fs after paroxysmal episodes associated with fever is often hindered by the lack of an objective biomarker with the widespread application of technologies, such as molecular biology, in medicine, some biomarkers for predicting or diagnosing fs have attracted attention. imuekemhe et al in 1989 and 1996 found that lactic acid in the serum and cerebrospinal fluid of children with fs was significantly increased . arginin-vasopressin hormone avp released by the pituitary gland, has been shown to be involved in the thermoregulatory response to fever and convulsions although avp is unstable in the peripheral blood and, therefore, unsuited for diagnostic use the c-terminal portion of the avp precursor copeptin has been recognized as a robust marker of avp secretion . wellman et al. found that the serum copeptin and von willebrand factor of children with fs were significantly higher than those of the control group .


Eligibility criteria:
inclusion criteria: * age from 6 months to 6 years. * seizures. * fever (≥38°c). exclusion criteria: * central nervous system infection. * epilepsy. * previous neurological abnormalities. * inborn errors of metabolism. * immunological diseases. * endocrinal diseases (e.g., diabetes mellitus). * obesity. * eating disorders. * gastrointestinal disorders (e.g., diarrhea).
heat stress and volume administration

Conditions: Syncope

Summary: heat stress reduces the central blood volume and causes orthostatic intolerance. the hypothesis is that infusion of volume may reduce effects of orthostatic stress during heat stress.


Eligibility criteria:
inclusion criteria: * age \> 18 \< 40 exclusion criteria: * abnormal medical history
mindful steps 2.0: promoting physical activity in patients with copd and hf

Conditions: Chronic Obstructive Pulmonary Disease; Chronic Heart Failure

Summary: the goal of this fully-remote randomized controlled trial is to test the efficacy of mindful steps in facilitating physical activity compared to usual standard of care among 136 patients with copd and/or hf. the main question it aims to answer is can this intervention promote physical activity as measured by daily step counts in sedentary patients with copd and/or hf. participants will be randomized (1:1 ratio) to receive either the mindful steps intervention or usual care for 12 months, with both arms receiving a walking for health education booklet.

this is a 2-arm parallel remotely delivered rct. a total of 136 participants with copd and/or hf will be randomized in a 1:1 ratio to one of 2 arms in a pragmatic design: 1) mindful steps multi-modal intervention, or 2) usual care (including an education booklet on walking). subjects will participate in the intervention for 12 months. testing will occur at baseline, 3, 6, 12 (end intervention), and 15 months (post-intervention follow up) for all participants. physical activity as measured by pedometer (i.e., daily step counts) at 12 months is the primary outcome to assess the efficacy of the mindful steps intervention. secondary outcomes include cognitive-behavioral measures that may relate to behavior change in a conceptual model (self-efficacy, intrinsic motivation, mindful awareness/interoception) as well as patient-centered clinical outcomes (hrql, dyspnea, fatigue, pa engagement, sedentary behavior).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd (defined as cigarette smoking history \> 10 pack-years, and either a ratio of fev1 to forced vital capacity \< 0.70 or chest ct evidence of emphysema) or clinical diagnosis of hf syndrome (with left ventricular systolic dysfunction or preserved ejection fraction and new york heart association class 1-3) * medical clearance from provider to participate in an exercise program * have an active email account; access to a computer device (desktop, laptop, tablet, or smartphone that supports the fitbit app). exclusion criteria: * copd or hf exacerbation in the previous month * inability to ambulate * inability to collect at least 7 of 14 days of baseline step counts * current participation in a cardiac or pulmonary rehabilitation program

Keywords: mind-body exercise fitbit mindful steps
safety and efficacy of novatears® + omega-3 (0.2%) eye drops on signs and symptoms of dry eye

Conditions: Evaporative Dry Eye Disease

Summary: this pmcf study is carried out following successful ce marking of novatears® + omega-3 and is intended to generate systematic clinical data on the safety and performance of the device when used in accordance with the intended purpose.


Eligibility criteria:
inclusion criteria: * signed icf (informed consent form) and data protection form * patient-reported history of ded in both eyes * have an ocular surface disease index (osd) score ≥ 25 at visit 1 * have meibomian gland dysfunction (mgd) at visit 1. * ability and willingness to follow instructions, including participation in all study assessments and visits exclusion criteria: * women who are pregnant, nursing or planning a pregnancy * ocular surface pathology, clinically significant slit-lamp findings, abnormal lid anatomy, active ocular allergies * wear of contact lenses * known allergy or sensitivity to the medical device or its components * currently enrolled in an investigational drug or device study or have used an investigational drug or device within 60 days before visit 1. * clinical site employees or immediate family members of the same
comparison of kinesiophobia, balance, falling and walking speeds of elderly's with physical frailty with alzheimer's

Conditions: Alzheimer Disease; Frail Elderly Syndrome

Summary: in this study, kinesiophobia, balance, falling, walking speeds of elderly people with cognitive frailty with alzheimer's dementia, elderly with physical frailty and healthy elderly individuals will be compared.

in this study, kinesiophobia, balance, falling, walking speeds of elderly people with cognitive frailty with alzheimer's dementia, elderly with physical frailty and healthy elderly individuals will be compared. for research, 3 groups will be included, including elderly individuals diagnosed with alzheimer's dementia, physically fragile elderly individuals and healthy elderly individuals staying at the private dikmen nursing home and the private uluçınar nursing home. the research will be conducted with a total of 54 individuals who voluntarily participated in the study from june 2023 to february 2024. the criteria for participation in the study of elderly individuals diagnosed with 1st group alzheimer's dementia are to be over 65 years old, to be able to walk independently and to be diagnosed with early or middle stage alzheimer's by a doctor. the criteria for participation in the study of physically frail elderly individuals for 2nd group is to be over 65 years old, to be able to walk independently and appearing fragile or pre-frail according to the frail questionnaire. the criteria for participation in the study of the 3rd group of healthy elderly individuals were to be over 65 years old, not to have any psychiatric, neurological and orthopedic problems, and to be able to walk independently. as a data collection tool; for the descriptive characteristics of the patients, a form containing demographic information will be used. timed up and go test, berg balance scale, 2 minutes walking test will be used to evaluate balance and gait. frail questionnaire and clinical frailty scale will be used for the evaluation of frailty. tampa scale will be used for kinesiophobia assessment. the fall activity scale (tinetti) will be used to assess the fear of falling. in addition, the cognitive status of individuals will be evaluated with the mini mental state test and the montreal cognitive assessment test.

Eligibility criteria:
inclusion criteria: * being over the age of 65 and being able to walk independently. * individuals who have been diagnosed with early or mid-stage alzheimer's by a physician. * appearing fragile or pre-frail according to the frail questionnaire. exclusion criteria: * who has an obstacle to doing physical activity. * those who have undergone an operation in the last 6 months. * those who do not agree to participate in the research. * those who have been diagnosed with late-stage alzheimer's dementia.

Keywords: accidental falls alzheimer disease frail elderly frailty kinesiophobia postural balance walking speed
celebrex with preoperative chemoradiation - rectal cancer

Conditions: Colorectal Neoplasms

Summary: colorectal carcinoma is the third most common cause of death from cancer. approximately, 30% of colorectal carcinomas involve the rectum. optimizing local control in the pelvis while reducing treatment toxicity remains one of the principal goals of therapy for patients with locally advanced rectal carcinoma. treatment strategies that achieve this goal will have a significant impact on our society.c linical trials have shown that this type of cancer is less likely to come back if chemotherapy and radiotherapy are added to surgery. a combination of all three types of therapy is now standard. celecoxib (celebrex®) is a drug that lessens the action of an enzyme called cyclooxygenase-2 (cox-2) also known as a "cox-2 inhibitor". it is an anti-inflammatory capsule (drug that reduces irritation) that is commonly used to treat arthritis. it is not a chemotherapy drug. laboratory experiments have shown that such cox-2 inhibitors may increase the anti-cancer effect of radiotherapy, without increasing radiation side effects. this has not yet been confirmed in humans.the main purpose of this study is to confirm that celecoxib does not increase the side effects when given with radiotherapy and chemotherapy for rectal cancer. we shall also be looking at how effective the combination of radiotherapy, chemotherapy and celecoxib is in shrinking rectal cancer.


Eligibility criteria:
inclusion criteria: * patients with resectable or potentially resectable adenocarcinoma of the rectum * clinical stage t2 n1-2 or t3-4 n0-2 (patients who require diverting loop colostomy are eligible) * age greater than 18 years, ecog performance status \< 2 (appendix, section 13.1) * biopsy proven adenocarcinoma, superior margin of the tumour within 15cm of the anal verge on rigid sigmoidoscopy exclusion criteria: * distant metastasis, prior pelvic irradiation, inflammatory bowel disease, medical conditions which preclude radical therapy * history of malignancy within five years (except nonmelanoma skin cancer, cin cervix) * pregnancy * hypersensitivity to celecoxib, nsaid, sulfonamides or 5-fu * significant comorbid illness * history of peptic ulcer disease or nsaid-related gastrointestinal bleeding * use of aspirin, other nsaid or coxib in the two weeks prior to study entry * neutrophil count \ 1.25xuln (upper limit of normal), ast/alt \>3xuln, serum creatinine \>1.25xuln
the efficacy of additional intravesical instillation of hyaluronic acid/chondroitin sulfate to transurethral resection of bladder ulcer in patients with interstitial cystitis/bladder pain syndrome.

Conditions: Interstitial Cystitis

Summary: the purpose of this study is to evaluate efficacy and safety of additional hyaluronic acid/chondroitin sulfate to transurethral resection of bladder ulcer in patient with interstitial cystitis.

this is a randomized, parallel, 6 month period study.

Eligibility criteria:
inclusion criteria: 1. must have experienced bladder pain, urinary urgency and urinary frequency, for at least 6 months prior to entry into the study 2. pain vas ≥4 3. o'leary-sant interstitial cystitis questionnaire (ic-q) symptom and problem ≥ 12( and pain ≥2, and nocturia ≥ 2) 4. puf score ≥ 13 5. cystoscopic record within 2 years 6. hunner ulcer lesion in cystoscopic finding exclusion criteria: 1. scheduled for or use of intravesical therapy (eg, bladder distention,transurethral resection of bladder ulcer, instillation) during or within 6months prior to the study and use of pentosan polysulfate sodium within 1 months prior to the study 2. patients who are pregnancy or, childbearing age without no contraception 3. patients with voided volume \ 400ml 4. patients with microscopic hematuria, (≥1+ in dipstick), if not excluded that no evidence of neoplastic tumor examination 5. patients with urine culture showing evidence of urinary tract infection 1month prior to the study 6. accompanied medical problem below * tuberculosis in urinary system * bladder cancer, urethral cancer, prostate cancer * recurrent cystitis * anatomical disorder 7. patients had prior surgery (eq, bladder augmentation, cystectomy 8. patients with neurologic disorder 9. patients with indwelling catheter or intermittent self-catheterization 10. patients with psychologic problem